

Volume 38 1974

Psycho— pharmacologia

Managing Editors

H. Barry III J. O. Cole M. Hamilton E. Jacobsen R. W. Russell

Editorial Board

H. Barry III, Pittsburgh D. Bovet, Roma J. O. Cole, Boston J. Delay, Paris
J. Elkes, Baltimore M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömberg, Risskov A. Wikler, Lexington

Supporting Editors

M. Adler, Philadelphia N.-E. Andén, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Blaschko, Oxford D. Booth, Birmingham
H. Brill, New York P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. P. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hind, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Chicago W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvett, Lyon C. R. B. Joyce, Basel D. Joyce, Perpignan
M. Katz, Rockville, MD R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. G. Laties, Rochester A. Latz, Boston
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. F. Mirsky, Boston C. Niemegeers, Beerse S. Norton, Kansas City
D. H. Overstreet, Bedford Park, S. Australia D. Overton, Philadelphia G. Pampiglione, London
P. Pichot, Paris R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom
K. Rickels, Philadelphia R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles
J. Scheel-Krüger, Roskilde J. Schildkraut, Boston C. Schuster, Chicago R. Shader, Boston
C. Shagass, Philadelphia P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm
J. R. Smythies, Edinburgh F. Sulser, Nashville R. Taber, Bloomfield J. Tecce, Boston
T. Thompson, Minneapolis S. Udenfriend, Nutley, NJ H. Weil-Malherbe, Washington
A. Weissman, Groton, CT T. Yanagita, Kawasaki E. Zaimis, London O. Zangwill, Cambridge



Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1974

Contents

Adler, R., Lomazzi, F.: Mild Analgesics Evaluated with the "Submaximum Effort Tourniquet Technique". I. The Influence of Psychological Factors on Their Effect	351
Adler, R., Gervasi, A., Holzer, B., Hemmeler, W.: Mild Analgesics Evaluated with the "Submaximum Effort Tourniquet Technique". II. The Influence of Tranquilizer on Their Effect	357
Aikens, A. M., see Schwartz, M. A., <i>et al.</i>	319
Alpern, H. P., see Stripling, J. S.	187
Amit, Z., see Ziskind, D., <i>et al.</i>	231
Andén, N.-E., Strömbom, U.: Adrenergic Receptor Blocking Agents: Effects on Central Noradrenaline and Dopamine Receptors and on Motor Activity	91
Bättig, K., see Driscoll, P.	47
Banerjee, U.: Programmed Self-Administration of Potentially Addictive Drugs in Young Rats and Its Effects on Learning	111
Baum, M., see Ziskind, D., <i>et al.</i>	231
Bigelow, G., see Griffiths, R., <i>et al.</i>	105
Bjurström, H., see Frankenhaeuser, M., <i>et al.</i>	271
Blackman, D. E., see Sanger, D. J., <i>et al.</i>	159
Blampied, N. M., see Stewart, W. J., <i>et al.</i>	55
Bohuon, C., see Poitou, P., <i>et al.</i>	75
Borsy, J., see Székely, J. I., <i>et al.</i>	339
Bos, E. R. H., see Praag, H. M. van, <i>et al.</i>	267
Brancati, A., see Caro, G. de, <i>et al.</i>	211
Burg, W. van den, see Praag, H. M. van, <i>et al.</i>	267
Caro, G. de, Micossi, L. G., Venturi, F., Brancati, A., Scarnati, E.: Behavioural and Electrocortical Modifications Induced in the Rat by Intraventricular Injection of Physalaemin and Eledoisin	211
Coper, H., see Fernandes, M., <i>et al.</i>	329
Dale, R., see Rolls, E. T., <i>et al.</i>	219
Dols, L. C. W., see Praag, H. M. van, <i>et al.</i>	267
Driscoll, P., Bättig, K.: Effects of Nicotine on the Shuttlebox Behavior of Trained Guinea Pigs	47
Dunne, E., see Frankenhaeuser, M., <i>et al.</i>	271
Fernandes, M., Schabarek, A., Coper, H., Hill, R.: Modification of Δ^9 -THC-Actions by Cannabinol and Cannabidiol in the Rat	329
Frankenhaeuser, M., Dunne, E., Bjurström, H., Lundberg, U.: Counteracting Depressant Effects of Alcohol by Psychological Stress	271
Frankenheim, J. M.: Effects of Repeated Doses of <i>l</i> - Δ^8 - <i>trans</i> -Tetrahydrocannabinol on Schedule-Controlled Temporally-Spaced Responding of Rats	125
Gervasi, A., see Adler, R., <i>et al.</i>	357
Gilbert, R. M.: Schedule-Induced Ethanol Polydipsia in Rats with Restricted Fluid Availability	151
Gillin, J. C., see Kaplan, J., <i>et al.</i>	239
Goudie, A. J., Taylor, M., Wheeler, T. J.: Chronic Anorexic and Behavioral Effects of the Fenfluramine Metabolite, Norfenfluramine: An Evaluation of Its Role in the Actions of Fenfluramine	67
Greizerstein, H. B., Smith, C. M.: Ethanol in Goldfish: Effect of Prior Exposure in a Test Procedure	345

Griffiths, R., Bigelow, G., Liebson, I.: Assessment of Effects of Ethanol Self-Administration on Social Interactions in Alcoholics	105
Guerinot, F., see Poitou, P., <i>et al.</i>	75
Hemmeler, W., see Adler, R., <i>et al.</i>	357
Hill, R., see Fernandes, M., <i>et al.</i>	329
Holzer, B., see Adler, R., <i>et al.</i>	357
Hughes, R. N., see Stewart, W. J., <i>et al.</i>	55
Izquierdo, I.: Effect on Pseudoconditioning of Drugs with Known Central Nervous Activity	259
Kaplan, J., Mandel, L. R., Stillman, R., Walker, R. W., Van den Heuvel, W. J. A., Gillin, J. C., Wyatt, R. J.: Blood and Urine Levels of N,N-Dimethyltryptamine Following Administration of Psychoactive Dosages to Human Subjects	239
Kelly, P. H., see Rolls, E. T., <i>et al.</i>	219
Key, M., see Sanger, D. J., <i>et al.</i>	159
Király, I., see Székely, J. I., <i>et al.</i>	339
Kornetsky, C., see Marcus, R.	1
Lader, M., see Tansella, M., <i>et al.</i>	81
Liebson, I., see Griffiths, R., <i>et al.</i>	105
Lomazzi, F., see Adler, R.	351
Lundberg, U., see Frankenhaeuser, M., <i>et al.</i>	271
Mandel, L. R., see Kaplan, J., <i>et al.</i>	239
Marcus, R., Kornetsky, C.: Negative and Positive Intracranial Reinforcement Thresholds: Effects of Morphine	1
Matthies, H., see Singh, H. K., <i>et al.</i>	247
Micossi, L. G., see Caro, G. de, <i>et al.</i>	211
Morrison, C. F.: Effects of Nicotine and Its Withdrawal on the Performance of Rats on Signalled and Unsignalled Avoidance Schedules	25
Morrison, C. F.: Effects of Nicotine on the Observed Behaviour of Rats during Signalled and Unsignalled Avoidance Experiments	37
Niemegeers, C. J. E., see Wauquier, A.	201
Ott, T., see Singh, H. K., <i>et al.</i>	247
Overstreet, D. H., see Vasquez, B. J., <i>et al.</i>	287
Parker, R. B.: Mouse Locomotor Activity: Effect of Morphine Narcotic Antagonists, and the Interaction of Morphine and Narcotic Antagonists	15
Poitou, P., Guerinot, F., Bohuon, C.: Effect of Lithium on Central Metabolism of 5-Hydroxytryptamine.	75
Praag, H. M. van, Burg, W. van den, Bos, E. R. H., Dols, L. C. W.: 5-Hydroxytryptophan in Combination with Clomipramine in "Therapy-Resistant" Depressions	267
Raskin, A., see Schulterbrandt, J. G., <i>et al.</i>	303
Reatig, N., see Schulterbrandt, J. G., <i>et al.</i>	303
Reichenberg, K., see Vetulani, J., <i>et al.</i>	173
Rolls, B. J., see Rolls, E. T., <i>et al.</i>	219
Rolls, E. T., Rolls, B. J., Kelly, P. H., Shaw, S. G., Wood, R. J., Dale, R.: The Relative Attenuation of Self-Stimulation, Eating and Drinking Produced by Dopamine-Receptor Blockade	219
Russell, R. W., see Vasquez, B. J., <i>et al.</i>	287
Sanger, D. J., Key, M., Blackman, D. E.: Differential Effects of Chlordiazepoxide and <i>d</i> -Amphetamine on Responding Maintained by a DRL Schedule of Reinforcement	159
Scarnati, E., see Caro, G. de, <i>et al.</i>	211
Schabarek, A., see Fernandes, M. <i>et al.</i>	329
Schulterbrandt, J. G., Raskin, A., Reatig, N.: True and Apparent Side Effects in a Controlled Trial of Chlorpromazine and Imipramine in Depression	303

Schwartz, M. A., Aikens, A. M., Wyatt, R. J.: Monoamine Oxidase Activity in Brains from Schizophrenic and Mentally Normal Individuals	319
Shaw, S. G., see Rolls, E. T., <i>et al.</i>	219
Simpson, L. L.: The Effects of Lithium and Physostigmine on Rat Brain Acetylcholinesterase Activity	145
Simpson, L. L.: A Study of the Interaction between Amphetamine and Food Deprivation	279
Singh, H. K., Ott, T., Matthies, H.: Effect of Intrahippocampal Injection of Atropine on Different Phases of a Learning Experiment	247
Smith, C. M., see Greizerstein, H. B.	345
Stewart, W. J., Blampied, N. M., Hughes, R. N.: The Effects of Scopolamine on Performance on a Geometric Progressive Ratio Schedule	55
Stillman, R., see Kaplan, J., <i>et al.</i>	239
Stripling, J. S., Alpern, H. P.: Nicotine and Caffeine: Disruption of the Long-Term Store of Memory and Proactive Facilitation of Learning in Mice	187
Strömbom, U., see Andén, N.-E.	91
Székely, J. I., Borsy, J., Király, I.: Potentiation of Tetrabenazine-Induced Behavioural Depression by Imipramine on a Discrete-Trial Avoidance Escape Schedule.	339
Tansella, M., Zimmermann-Tansella, C., Lader, M.: The Residual Effects of N-Desmethyldiazepam in Patients	81
Taylor, M., see Goudie, A. J., <i>et al.</i>	67
Tonge, S. R.: Noradrenaline and 5-Hydroxytryptamine Metabolism in Six Areas of Rat Brain during Post-Amphetamine Depression	181
Van den Heuvel, W. J. A., see Kaplan, J., <i>et al.</i>	239
Vasquez, B. J., Overstreet, D. H., Russel, R. W.: Psychopharmacological Evidence for Increase in Receptor Sensitivity following Chronic Morphine Treatment	287
Venturi, F., see Caro, G. de, <i>et al.</i>	211
Vetulani, J., Reichenberg, K., Wiszniowska, G.: The Ineffectiveness of Desipramine Pretreatment on Behavioral Effects of 6-Hydroxydopamine in Nialamide-Pretreated Rats	173
Walker, R. W., see Kaplan, J., <i>et al.</i>	239
Wauquier, A., Niemegeers, C. J. E.: Intracranial Self-Stimulation in Rats as a Function of Various Stimulus Parameters	201
Wheeler, T. J., see Goudie, A. J., <i>et al.</i>	67
Wiszniowska, G., see Vetulani, J., <i>et al.</i>	173
Wood, R. J., see Rolls, E. T., <i>et al.</i>	219
Wyatt, R. J., see Kaplan, J., <i>et al.</i>	239
Wyatt, R. J., see Schwartz, M. A., <i>et al.</i>	319
Zimmermann-Tansella, C., see Tansella, M., <i>et al.</i>	81
Ziskind, D., Amit, Z., Baum, M.: Resistance to Extinction of an Avoidance Response in Rats Following the Administration of Chlordiazepoxide (Librium) or Diazepam (Valium)	231

The first of these is the fact that the
the second is the fact that the
the third is the fact that the
the fourth is the fact that the
the fifth is the fact that the
the sixth is the fact that the
the seventh is the fact that the
the eighth is the fact that the
the ninth is the fact that the
the tenth is the fact that the
the eleventh is the fact that the
the twelfth is the fact that the
the thirteenth is the fact that the
the fourteenth is the fact that the
the fifteenth is the fact that the
the sixteenth is the fact that the
the seventeenth is the fact that the
the eighteenth is the fact that the
the nineteenth is the fact that the
the twentieth is the fact that the
the twenty-first is the fact that the
the twenty-second is the fact that the
the twenty-third is the fact that the
the twenty-fourth is the fact that the
the twenty-fifth is the fact that the
the twenty-sixth is the fact that the
the twenty-seventh is the fact that the
the twenty-eighth is the fact that the
the twenty-ninth is the fact that the
the thirtieth is the fact that the
the thirty-first is the fact that the
the thirty-second is the fact that the
the thirty-third is the fact that the
the thirty-fourth is the fact that the
the thirty-fifth is the fact that the
the thirty-sixth is the fact that the
the thirty-seventh is the fact that the
the thirty-eighth is the fact that the
the thirty-ninth is the fact that the
the fortieth is the fact that the
the forty-first is the fact that the
the forty-second is the fact that the
the forty-third is the fact that the
the forty-fourth is the fact that the
the forty-fifth is the fact that the
the forty-sixth is the fact that the
the forty-seventh is the fact that the
the forty-eighth is the fact that the
the forty-ninth is the fact that the
the fiftieth is the fact that the
the fifty-first is the fact that the
the fifty-second is the fact that the
the fifty-third is the fact that the
the fifty-fourth is the fact that the
the fifty-fifth is the fact that the
the fifty-sixth is the fact that the
the fifty-seventh is the fact that the
the fifty-eighth is the fact that the
the fifty-ninth is the fact that the
the sixtieth is the fact that the
the sixty-first is the fact that the
the sixty-second is the fact that the
the sixty-third is the fact that the
the sixty-fourth is the fact that the
the sixty-fifth is the fact that the
the sixty-sixth is the fact that the
the sixty-seventh is the fact that the
the sixty-eighth is the fact that the
the sixty-ninth is the fact that the
the seventieth is the fact that the
the seventy-first is the fact that the
the seventy-second is the fact that the
the seventy-third is the fact that the
the seventy-fourth is the fact that the
the seventy-fifth is the fact that the
the seventy-sixth is the fact that the
the seventy-seventh is the fact that the
the seventy-eighth is the fact that the
the seventy-ninth is the fact that the
the eightieth is the fact that the
the eighty-first is the fact that the
the eighty-second is the fact that the
the eighty-third is the fact that the
the eighty-fourth is the fact that the
the eighty-fifth is the fact that the
the eighty-sixth is the fact that the
the eighty-seventh is the fact that the
the eighty-eighth is the fact that the
the eighty-ninth is the fact that the
the ninetieth is the fact that the
the ninety-first is the fact that the
the ninety-second is the fact that the
the ninety-third is the fact that the
the ninety-fourth is the fact that the
the ninety-fifth is the fact that the
the ninety-sixth is the fact that the
the ninety-seventh is the fact that the
the ninety-eighth is the fact that the
the ninety-ninth is the fact that the
the hundredth is the fact that the

Subject Index

A

Acetylcholinesterase 145
 Activity analysis 67
 Addictive drugs 111
 Adrenalectomy 279
 Adrenergic drugs 287
 Alcohol 271
 Alcoholics 105
d-Amphetamine 159, 181, 279
 Amylobarbitone sodium 81
 Analeptics 259
 Analgesia 1
 Analgesics, mild 351, 357
 Anorexia 67
 Anticholinergics 55
 Anticonvulsants 259
 Antidepressants 339
 Apomorphine 91
 Avoidance 25, 37, 231

B

Barbiturates 259
 Behavior 211
 Behavioral pharmacology 125
 Body temperature 329
 Brain amine 75
 —, catecholamines 173
 —, serotonin 75

C

Caffeine 187
 Cannabidiol 329
 Cannabinol 329
 Cannabis 125
 Catalepsy 329
 Catecholamine receptor blockade 91
 Chlordiazepoxide 159, 231
 Chlorpromazine 303
 Cholinergic blockade 55
 —, drugs 287
 —, system 247
 Chromatography, gas 239
 Clomipramine 267
 Clonidine 91
 Cocaine 201
 Conditional reflex activity 339
 Conditioned learning 111
 Consolidation 247

D

Depression 181, 267, 303
 Desipramine 173

Diazepam 231
 Dissociation 25
 Dopamine 219
 Drinking 219
 DRL responding 125, 159
 Drug-behavior interaction 271
 Drug dependence 111

E

Eating 219
 EEG 211
 Electric shock 271
 Eleodoisin 211
 Ethanol 105, 345
 —, drinking 151
 Extinction 111, 247
 —, resistance to 231
 Excessive behavior 151

F

Fenfluramine 67
 Fixed-time schedules 151
 Food deprivation 279
 —, intake 329
 FR5 responding 287
 Freezing 37

G

Guinea pigs 47
 Goldfish 345

H

Hexobarbitone 329
 Hippocampus 247
 Human subjects 81, 105, 239, 267, 271, 303, 319, 351, 357
 6-Hydroxydopamine 173, 279
 5-Hydroxytryptamine 75
 5-Hydroxytryptophan 267
 Hypnotic effects 81

I

Imipramine 303, 339
 Interaction 329
 Intercranial reinforcement 1
 Intraventricular injection 211
 Ischemic muscle pain 351, 357

L

Learning 247
 —, facilitation 187

VIII

Subject Index

- Lithium 75, 145
 Locomotor activity 15, 173
- M**
- Marijuana 125, 329
 Maze learning 111
 Medial forebrain bundle 1, 201
 Memory disruption 187
 Mice 15, 187
 Monoamine oxidase 319
 Monoamines 181
 Morphine 1, 15
 —, tolerance 287
 Mortality 173
 Motility 329
 Motor activity 91
- N**
- Narcotics 1
 —, antagonists 15
 N-Desmethyldiazepam 81
 Neurological impairment 111
 Nicotine 37, 47, 187
 —, dependence 25
 N,N-Dimethyltryptamine 239
 Norfenfluramine 67
- O**
- Observed behavior 37
 Open field performance 173
 Overturn point 345
- P**
- Pain 1
 Peptides 211
 Performance decrement 47
 —, tasks 81
 Phenoxybenzamine 91
 Physalaemin 211
 Physostigmine 145
 Polydipsia 151
 Progressive ratio 55
 Propranolol 91
 Pseudoconditioning 259
 Psychological factors 351
 —, stress 271
- Psychomotor performance 271
 Psychotomimetic 239
- R**
- Rat brain 145
 Rats 1, 25, 37, 55, 67, 75, 91, 111, 125, 145, 151, 159, 173, 181, 201, 211, 219, 231, 247, 259, 279, 287, 329, 339
 Receptor sensitivity, increased 287
 Residual effects 81
 Reticular formation 1
 "Reverse tolerance" 125
- S**
- Schedule-induced polydipsia 151
 Schizophrenia 239, 319
 Scopolamine 55
 Sedation, unspecific 91
 Self-stimulation 1, 201, 219
 Sensitivity 125
 Shuttlebox behavior 47
 Side-effects 303
 Sidman avoidance 25
 Social interactions 105
 Spectrometry, mass 239
 Spiroperidol 219
 Stress 25
 Substance P 211
 Sympathectomy 279
- T**
- Tetrabenazine 339
 Δ^9 THC 125
 Δ^9 THC 329
 Threshold determination 1
 Tolerance 125, 345
 Tranquilizers 259, 357
- V**
- Various stimulus parameter conditions 201
- W**
- Warmup 25
 Water intake 329

Instructions to Authors

1. Papers will be published in **English, French or German.**
2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.
3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.
4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.
5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).
6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**
7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.
8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.
9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.
10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*
Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. *Psychopharmacologia (Berl.)* **14**, 23–32 (1960).
Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: *Neuropsychopharmacology*. Bradley, P. B., Flugle, F., and Hoch, P., Eds., Vol. 3, pp. 149–156. Amsterdam: Elsevier 1964.
Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that..." When a paper with more than two authors is cited, only the first need be named, followed by "*et al.*".
11. **Figures** should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped**, bearing in mind maximum display area is 108×177 mm ($4\frac{1}{4} \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the block-maker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

How many hours do you spend just looking for the articles you want to read?

- ☐ 1 hr. per week
- ☐ 2 hrs. per week
- ☐ 3 hrs. per week

That's how many hours ASCA® will save you.

If you're typical of most researchers, it's been shown that you spend up to one-fourth of your time just trying to keep abreast of advances in your field. And that includes many hours just looking for the articles. One, two, maybe three hours that ASCA can save you every week. For only \$3 a week.

ASCA (*Automatic Subject Citation Alert*) saves your time by finding these important articles for you. You simply tell us what subjects interest you. What authors. What research. And we'll prepare a personal computer profile for you which reflects your exact reading interests no matter how narrow or wide ranging they

may be. Then each week, ASCA's computer compares this profile with the articles in 3,500 leading scientific and technical journals and prints out a custom-tailored list telling you which articles to read and exactly where to find them.

But you'll never know how much time ASCA can save you until you try it. Give an ASCA information specialist a call (215-923-3300) and ask about our 13-week, \$39 introductory offer. Or fill in and mail the coupon below. Then think about what you're going to do with all the time you'll save.

©1974 ISI

isi® Institute for Scientific Information
325 Chestnut Street, Philadelphia, Pennsylvania 19106

SV-394

- ☐ I'd like to take advantage of your introductory offer and try ASCA® for 13 weeks at \$39. Please contact me. (Trial offer is limited to residents of the continental United States, Europe, and Mexico.)

Name _____

Position _____

Organization _____

Address _____

City _____

State _____

Zip _____

Country _____

Telephone _____

Extension _____

Responsible for advertisement: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237

Telephone: (030) 882 1031, Telex: 01-85411

Springer-Verlag, Berlin · Heidelberg · New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin · Heidelberg 1974

